Comments on: Insilico Medicine Nominates ISM5059, the Peripheral-restricted NLRP3 Inhibitor as Preclinical Candidate, for the Treatment of Multiple Inflammatory and Metabolism Indications

Comments on: Insilico Medicine Nominates ISM5059, the Peripheral-restricted NLRP3 Inhibitor as Preclinical Candidate, for the Treatment of Multiple Inflammatory and Metabolism Indications https://9krapalm.com/insilico-medicine-nominates-ism5059-the-peripheral-restricted-nlrp3-inhibitor-as-preclinical-candidate-for-the-treatment-of-multiple-inflammatory-and-metabolism-indications/ เสิร์ฟข่าวไอที อัปเดตเทคโนโลยีสไตล์ @krapalm Thu, 05 Feb 2026 13:26:44 +0000 hourly 1 https://wordpress.org/?v=7.0.1